Idioma:

Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone

Gómez-Revuelta, Marcos ; Pelayo-Terán, José María ; Juncal-Ruiz, María ; Vázquez-Bourgon, Javier ; Suárez-Pinilla, Paula ; Romero-Jiménez, Rodrigo ; Setién Suero, Esther ; Ayesa-Arriola, Rosa ; Crespo-Facorro, Benedicto

The international journal of neuropsychopharmacology, 2020-04, Vol.23 (4), p.217-229 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por

Enviar para

Título:
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone
Autor: Gómez-Revuelta, Marcos ; Pelayo-Terán, José María ; Juncal-Ruiz, María ; Vázquez-Bourgon, Javier ; Suárez-Pinilla, Paula ; Romero-Jiménez, Rodrigo ; Setién Suero, Esther ; Ayesa-Arriola, Rosa ; Crespo-Facorro, Benedicto
Assuntos: Adolescent ; Adult ; Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - pharmacology ; Antipsychotic drugs ; Aripiprazole - administration & dosage ; Aripiprazole - adverse effects ; Aripiprazole - pharmacology ; Comparative analysis ; Drug therapy ; Female ; Follow-Up Studies ; Haloperidol - administration & dosage ; Haloperidol - adverse effects ; Haloperidol - pharmacology ; Humans ; Male ; Olanzapine - administration & dosage ; Olanzapine - adverse effects ; Olanzapine - pharmacology ; Outcome Assessment, Health Care ; Piperazines - administration & dosage ; Piperazines - adverse effects ; Piperazines - pharmacology ; Psychoses ; Psychotic Disorders - drug therapy ; Quetiapine Fumarate - administration & dosage ; Quetiapine Fumarate - adverse effects ; Quetiapine Fumarate - pharmacology ; Regular s ; Risperidone - administration & dosage ; Risperidone - adverse effects ; Risperidone - pharmacology ; Schizophrenia - drug therapy ; Statistics ; Testing ; Thiazoles - administration & dosage ; Thiazoles - adverse effects ; Thiazoles - pharmacology ; Young Adult
É parte de: The international journal of neuropsychopharmacology, 2020-04, Vol.23 (4), p.217-229
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
Descrição: Different effectiveness profiles among antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to impact on long-term outcome. The aim of this study is to compare the clinical effectiveness of olanzapine, risperidone, haloperidol, aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up. From February 2001 to January 2011, 2 phases of a prospective, randomized, open-label study were undertaken. A total of 376 first-episode drug-naïve patients were randomly assigned to olanzapine (n = 55), risperidone (n = 63), haloperidol (n = 56), aripiprazole (n = 78), ziprasidone (n = 62), or quetiapine (n = 62) and followed up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an analysis based on intention-to-treat principle was conducted in the analysis for clinical efficacy. The overall dropout rate at 3 years reached 20.75%. Treatment discontinuation rates were significantly different among treatment groups (olanzapine = 69.09, risperidone = 71.43, aripiprazole = 73.08%, ziprasidone = 79.03%, haloperidol = 89.28%, and quetiapine = 95.53%) (χ2 = 79.86; P = .000). Statistically significant differences in terms of lack of efficacy, adherence, and tolerability were observed among treatment groups along the 3-year follow-up, determining significant differences in time to all-cause discontinuation (log-rank = 92.240; P = .000). Significant differences between treatments were found in the categories of sleepiness/sedation, increased sleep duration, akinesia, weight gain, ejaculatory dysfunction, extrapyramidal-symptoms, and amenorrhea. Olanzapine, risperidone, and aripiprazole presented advantages for the first-line treatment of first episode of psychosis in terms of effectiveness. Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis.ClinicalTrials.gov Identifier: NCT02526030 https://clinicaltrials.gov/show/NCT02526030.
Editor: England: Oxford University Press
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone

Gómez-Revuelta, Marcos ; Pelayo-Terán, José María ; Juncal-Ruiz, María ; Vázquez-Bourgon, Javier ; Suárez-Pinilla, Paula ; Romero-Jiménez, Rodrigo ; Setién Suero, Esther ; Ayesa-Arriola, Rosa ; Crespo-Facorro, Benedicto

England: Oxford University Press

Buscando em bases de dados remotas. Favor aguardar.